Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting, including new evidence in pulsed ...
RAPIBLYK® is an ultra-short-acting, selective beta-1 adrenergic receptor blocker administered intravenously in a monitored ...
A new study from King’s College London has introduced a promising drug that could help save people during heart attacks by stopping one of the most dangerous problems: a sudden, deadly change in heart ...
Atrial fibrillation (AF) is a predominant risk factor for heart failure, even in patients with preserved left ventricular ejection fraction. Emerging evidence suggests the significance of right ...
For patients with atrial fibrillation, the use of oral anticoagulant therapy to prevent stroke is limited by the risk of bleeding. Left atrial appendage closure is considered for patients who are ...
In these 2025 Advanced Life Support Guidelines, the American Heart Association provides comprehensive recommendations for the resuscitation and management of adults experiencing cardiac arrest, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results